Table 3.
Pharmacological intervention for GCX protection
| Authors | Study subjects | Substances | Insults | Results |
|---|---|---|---|---|
| Broekhuizen [67] | Patients | Sulodexide | Diabetes mellitus type 2 | GCX thickness increased |
| Gao [71] | Rats | Hydrocortisone | Pancreatitis | Improved intestinal perfusion Attenuation of Syn-1 and HA release |
| Nordling [72] | Endothelial cells | Immobilized heparin conjugate | IRI | Attenuation of thrombotic disorder |
| Strunden [75] | Isolated mouse lung | HES | Heparinase | HES attenuated interstitial edema, increased pulmonary arterial pressure |
| Chappell [70] | Isolated guinea pig heart | Corticosteroid | IRI | Increase in Syn-1 and reduction in HS |
| Chappell [79] | Isolated guinea pig heart | Sevoflurane | IRI | Increase in Syn-1 and reduction in HS |
IRI ischemia reperfusion injury